Evaluating the potential benefit of interferon treatment in multiple sclerosis

JAMA

Volumn 308, Issue 3, 2012, Pages 290-291

  Derfuss, Tobias ^a   Kappos, Ludwig ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GLATIRAMER; INTERFERON;

DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EXPANDED DISABILITY STATUS SCALE; HUMAN; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION;

EID: 84863959078     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.8327     Document Type: Editorial

References (16)

1. World Health Organization; Multiple Sclerosis International Federation. Multiple Sclerosis Resources in the World. Geneva, Switzerland: World Health Organization; 2008.
2. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability. Brain. 1989;112(pt 1):133-146. (Pubitemid 19056478)
3. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006;66(2):172-177. (Pubitemid 43970148)
4. Goodin DS, Frohman EM, Garmany GP Jr, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis. Neurology. 2002;58(2):169-178. (Pubitemid 34086933)
5. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology. 2007;69(15):1498-1507. (Pubitemid 47537856)
6. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis [published online May 31, 2012]. Mult Scler. doi:10.1177/1352458512445941.
7. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-285. (Pubitemid 28065253)
8. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 2002;125(pt 10):2202-2212.
9. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology. 2010;74(23):1868-1876.
10. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-953. (Pubitemid 44454583)
11. Freedman MS. Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology. 2011;76(1)(suppl 1):S26-S34.
12. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012;308(3):247-256.
13. Kappos L, Weinshenker B, Pozzilli C, et al; European (EU-SPMS) Interferon Beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon Beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the 2 trials. Neurology. 2004;63(10):1779-1787.
14. Shirani A, Zhao Y, Kingwell E, Rieckmann P, Tremlett H. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler. 2012;18(4):442-450.
15. Jacobs LD, Beck RW, Simon JH, et al CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343(13):898-904.
16. Kappos L, Freedman MS, Polman CH, et al BENEFIT Study Group. Longterm effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987-997.